Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 14Lymphoid 10Tumor-Agnostic 8Thoracic 8Other hematologic neoplasm 8Breast 8Gastrointestinal 6Gynecologic 4Dermatologic 3Head & Neck 2Genitourinary 2Sarcoma 1Plasma cell 1Other neoplasm 1Myeloid 1Classical hematology 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Melanoma 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Itraconazole × Genitourinary × Clear all
NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
862 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

AstraZeneca

Phase 1 Completed
11 enrolled
BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡